2017 American Transplant Congress
Biopsies (Bx) of Renal Allografts with Antibody- + Cell-Mediated Rejection (ABMR/CMR) Exhibit Gene Expression Signatures from Both Types of Rejection.
Background: In HLA-sensitized kidney transplant patients (Pts) the concomitant presence of ABMR/CMR on Bx is associated with a more severe and (&) usually irreversible injury…2017 American Transplant Congress
Accelerated De-Novo Donor-Specific Antibody-Mediated Rejection in a Non-Human Primate Model of Renal Transplantation.
Surgery - Division of Transplantation, University of Wisconsin-Madison, Madison, WI
The development of accelerated antibody-mediated rejection (ABMR) is associated with early allograft dysfunction and premature graft loss. In animals, pre-sensitization is usually required in order…2017 American Transplant Congress
Early and Late High Intrapatient Variability of Tacrolimus Levels Can Predict Late Renal Allograft Rejection.
Introduction Nonadherence to immunosuppressive medication can start any time after transplantation and is associated with rejection and graft loss. We have previously shown that high…2017 American Transplant Congress
Mechanistic Insights by RNA Profiling on Rejecting Vascularized Composite Allotransplants.
Background: Detailed molecular changes associated with rejection to vascularized composite allotransplants (VCA) are not well understood. Materials and Methods: peripheral blood was drawn from the…2017 American Transplant Congress
The Impact of Early Clinical and Subclinical T Cell Rejection After Kidney Transplantation.
Medicine and Surgery, University of Pittsburgh, Pittsburgh, PA
Purpose: To evaluate the impact of early Clinical(C-TCMR) and Sub-Clinical(SC-TCMR) T Cell Mediated Rejection on short-term allograft histology and function.Methods: We examined adult kidney alone…2017 American Transplant Congress
Tacrolimus Time in Therapeutic Range Predicts Adverse Clinical Outcomes in the First Year of Kidney Transplant.
University of Colorado, Aurora, CO
Tacrolimus (TAC) has a narrow therapeutic range, with its upper bounds limited by serious toxicities while TAC minimization strategies have demonstrated immunologic risk. Monitoring the…2017 American Transplant Congress
Multiple Dosing of Anti-C1s Antibody TNT009 – Effect on HLA Antibody-Triggered Complement Activation in Healthy Volunteers and Kidney Transplant Recipients with Antibody-Mediated Rejection.
Study purpose. Complement inhibition may be an attractive strategy to prevent antibody-mediated allograft injury. One promising therapeutic target may be the enzymatic activity of key…2017 American Transplant Congress
Composite Prognostic Score Improves Clinical Benefit in Kidney Recipients Receiving Standard of Care Therapy for Antibody-Mediated Rejection.
Paris Translational Research Center for Organ Transplantation, Paris, France
There is a marked heterogeneity in AMR patients' prognosis after SOC treatment including plasma exchange (PE) and intravenous immunoglobulins (IVIG). We investigated whether the use…2017 American Transplant Congress
In Clinic Systems to Address Adherence Barriers Decrease Late Allograft Rejection for Kidney Transplant Patients.
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background: Patient-identified barriers to taking immunosuppressive medications are associated with rejection and allograft loss in kidney transplant patients, yet interventions targeting adherence barriers are rarely…2017 American Transplant Congress
Impact of a B-Cell Targeting Agent on Antibody Mediated Rejection and Graft' Survival in Liver Transplantation with Preformed DSAs.
Introduction The negative impact of preformed anti-HLA donor specific antibodies (DSAs) in liver transplantation is clearly established. However, the potential interest of a B-cell depleting…
- « Previous Page
- 1
- …
- 121
- 122
- 123
- 124
- 125
- …
- 172
- Next Page »